210 related articles for article (PubMed ID: 20545943)
21. Hyperglycemia inhibits complement-mediated immunological control of S. aureus in a rat model of peritonitis.
Mauriello CT; Hair PS; Rohn RD; Rister NS; Krishna NK; Cunnion KM
J Diabetes Res; 2014; 2014():762051. PubMed ID: 25610878
[TBL] [Abstract][Full Text] [Related]
22. Staphylococcal complement evasion by various convertase-blocking molecules.
Jongerius I; Köhl J; Pandey MK; Ruyken M; van Kessel KP; van Strijp JA; Rooijakkers SH
J Exp Med; 2007 Oct; 204(10):2461-71. PubMed ID: 17893203
[TBL] [Abstract][Full Text] [Related]
23. Multiple Domains of Staphylococcal Superantigen-like Protein 11 (SSL11) Contribute to Neutrophil Inhibition.
Yang C; Barbieri JT; Dahms NM; Chen C
Biochemistry; 2022 Apr; 61(7):616-624. PubMed ID: 35285627
[No Abstract] [Full Text] [Related]
24. A Single-Domain Antibody Targeting Complement Component C5 Acts as a Selective Inhibitor of the Terminal Pathway of the Complement System and Thus Functionally Mimicks the C-Terminal Domain of the
Yatime L; Merle NS; Hansen AG; Friis NA; Østergaard JA; Bjerre M; Roumenina LT; Thiel S; Kristensen P; Andersen GR
Front Immunol; 2018; 9():2822. PubMed ID: 30555486
[TBL] [Abstract][Full Text] [Related]
25. Differential Interaction of the Staphylococcal Toxins Panton-Valentine Leukocidin and γ-Hemolysin CB with Human C5a Receptors.
Spaan AN; Schiepers A; de Haas CJ; van Hooijdonk DD; Badiou C; Contamin H; Vandenesch F; Lina G; Gerard NP; Gerard C; van Kessel KP; Henry T; van Strijp JA
J Immunol; 2015 Aug; 195(3):1034-43. PubMed ID: 26091719
[TBL] [Abstract][Full Text] [Related]
26. Laboratory Mice Are Frequently Colonized with
Schulz D; Grumann D; Trübe P; Pritchett-Corning K; Johnson S; Reppschläger K; Gumz J; Sundaramoorthy N; Michalik S; Berg S; van den Brandt J; Fister R; Monecke S; Uy B; Schmidt F; Bröker BM; Wiles S; Holtfreter S
Front Cell Infect Microbiol; 2017; 7():152. PubMed ID: 28512627
[TBL] [Abstract][Full Text] [Related]
27. Episodes of natural selection shaped the interactions of IgA-Fc with FcalphaRI and bacterial decoy proteins.
Abi-Rached L; Dorighi K; Norman PJ; Yawata M; Parham P
J Immunol; 2007 Jun; 178(12):7943-54. PubMed ID: 17548632
[TBL] [Abstract][Full Text] [Related]
28. Staphylococcal complement inhibitor modulates phagocyte responses by dimerization of convertases.
Jongerius I; Puister M; Wu J; Ruyken M; van Strijp JA; Rooijakkers SH
J Immunol; 2010 Jan; 184(1):420-5. PubMed ID: 19949103
[TBL] [Abstract][Full Text] [Related]
29. Staphylococcus aureus formyl peptide receptor-like 1 inhibitor (FLIPr) and its homologue FLIPr-like are potent FcγR antagonists that inhibit IgG-mediated effector functions.
Stemerding AM; Köhl J; Pandey MK; Kuipers A; Leusen JH; Boross P; Nederend M; Vidarsson G; Weersink AY; van de Winkel JG; van Kessel KP; van Strijp JA
J Immunol; 2013 Jul; 191(1):353-62. PubMed ID: 23740955
[TBL] [Abstract][Full Text] [Related]
30. Role of complement receptors 1 and 2 (CD35 and CD21), C3, C4, and C5 in survival by mice of Staphylococcus aureus bacteremia.
Cunnion KM; Benjamin DK; Hester CG; Frank MM
J Lab Clin Med; 2004 Jun; 143(6):358-65. PubMed ID: 15192652
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of C5a-induced inflammation with preserved C5b-9-mediated bactericidal activity in a human whole blood model of meningococcal sepsis.
Sprong T; Brandtzaeg P; Fung M; Pharo AM; Høiby EA; Michaelsen TE; Aase A; van der Meer JW; van Deuren M; Mollnes TE
Blood; 2003 Nov; 102(10):3702-10. PubMed ID: 12881318
[TBL] [Abstract][Full Text] [Related]
32. Protective role of complement C5a in an experimental model of Staphylococcus aureus bacteremia.
von Köckritz-Blickwede M; Konrad S; Foster S; Gessner JE; Medina E
J Innate Immun; 2010; 2(1):87-92. PubMed ID: 20375626
[TBL] [Abstract][Full Text] [Related]
33. Phagocytosis and killing of Staphylococcus aureus by bovine neutrophils after priming by tumor necrosis factor-alpha and the des-arginine derivative of C5a.
Rainard P; Riollet C; Poutrel B; Paape MJ
Am J Vet Res; 2000 Aug; 61(8):951-9. PubMed ID: 10951989
[TBL] [Abstract][Full Text] [Related]
34.
Pietrocola G; Nobile G; Rindi S; Speziale P
Front Cell Infect Microbiol; 2017; 7():166. PubMed ID: 28529927
[TBL] [Abstract][Full Text] [Related]
35. Colonization and infection of the human host by staphylococci: adhesion, survival and immune evasion.
Foster TJ
Vet Dermatol; 2009 Oct; 20(5-6):456-70. PubMed ID: 20178484
[TBL] [Abstract][Full Text] [Related]
36. Staphylococcus aureus innate immune evasion is lineage-specific: a bioinfomatics study.
McCarthy AJ; Lindsay JA
Infect Genet Evol; 2013 Oct; 19():7-14. PubMed ID: 23792184
[TBL] [Abstract][Full Text] [Related]
37. Neutrophils versus Staphylococcus aureus: a biological tug of war.
Spaan AN; Surewaard BG; Nijland R; van Strijp JA
Annu Rev Microbiol; 2013; 67():629-50. PubMed ID: 23834243
[TBL] [Abstract][Full Text] [Related]
38. Staphylococcal complement inhibitor: structure and active sites.
Rooijakkers SH; Milder FJ; Bardoel BW; Ruyken M; van Strijp JA; Gros P
J Immunol; 2007 Sep; 179(5):2989-98. PubMed ID: 17709514
[TBL] [Abstract][Full Text] [Related]
39. The role of TLR2 in vivo following challenge with Staphylococcus aureus and prototypic ligands.
Mullaly SC; Kubes P
J Immunol; 2006 Dec; 177(11):8154-63. PubMed ID: 17114491
[TBL] [Abstract][Full Text] [Related]
40. Staphylococcal superantigen-like protein 10 (SSL10) binds to human immunoglobulin G (IgG) and inhibits complement activation via the classical pathway.
Itoh S; Hamada E; Kamoshida G; Yokoyama R; Takii T; Onozaki K; Tsuji T
Mol Immunol; 2010 Jan; 47(4):932-8. PubMed ID: 19913916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
